Profil at EASD Annual Meeting 2018

About EASD Annual Meeting

Profil will be present at EASD Annual Meeting with numerous posters as well as some presentations. Of course we look forward to this exciting event very much. 

We are proud that Profil will be a sponsor of Solvable Problems in Diabetes at EASD Annual Meeting 2018 in Berlin. The event will take place on Thursday, October 4, 2018, from 7:00-9:00 pm during the 2018 annual meeting for the European Association of the Study of Diabetes (EASD). Learn more about the event here

To meet Profil at the EASD Annual Meeting please fill out the request form at our website.

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Sep 14, 2018 12:21:35 PM

Do-It-Yourself Artificial Pancreas systems (DIY APS)

The way forward to closed-loop metabolic control in diabetes care?

The challenge

Diabetes represents a huge and multidimensional challenge. Despite the availability of numerous treatment options, many patents still fail to reach their treatment goals. Administration of  the right amount of insulin at the right time still poses a great challenge for the self-management of many people with diabetes.

Accordingly there is a huge need to implement new innovative products and services improving both the effectiveness of diabetes care and the quality of life for people with diabetes. Particularly user-centered products and sercvices co-created with stakeholders including people with diabetes may have a high potential to increase treatment adherence thereby reducing the enormous pressure on healthcare systems.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Sep 5, 2018 5:16:00 PM

Targeting the incretin/glucagon system: a glimmer of hope

Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy

The rising prevalence of obesity has metabolic consequences such as diabetes and cardiovascular complications. Many existing therapies for type 2 diabetes mellitus (T2DM) focus on lowering blood glucose; however, there is a major unmet need for treatments that both improve glycemic control and achieve metabolic benefits by weight loss. Lifestyle interventions, such as dieting and physical activity, typically provide only short-lasting weight loss in obese people, as weight loss maintenance is the greatest barrier to successful treatment of obesity [1].


Read More

Topics: Treating Diabetes

Posted by Dr. Ulrike Hövelmann on Aug 28, 2018 5:11:00 PM

Free webinar on EU-funded R&D partnerships in healthy living and active ageing

Profil continues the successful series of scientific webinars. On September 12th we will air our webinar on "EU-funded R&D partnerships in healthy living and active ageing". The session is presented by Prof. Dr. Freimut Schliess, Director Science & Innovation at Profil and Jakob Haardt, Research & Innovation Manager at Eurice. 

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Aug 14, 2018 5:18:00 PM

Even moderate overweight increases the risk for cardiovascular disease, recent study says

A substantial amount of studies in the last decade have determined the detrimental effects of overweight and obesity on the risk of myocardial infarction, stroke, cancer, and overall mortality. Nonetheless, there is also evidence in favour of the so-called “obesity-paradox” which states that overweight - or even obesity - exerts a protective role or has no impact on the incidence of cardiovascular disease (CVD) and overall mortality, because of increased cardiovascular mortality in the lowest BMI strata (J-curve).

In March 2018, a study was published by researchers from the University of Glasgow, challenging the obesity-paradox and heating up the debate of this much-discussed topic [1].

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes, Clinical trials in Obesity

Posted by Dr. Daniela Lamers on Aug 7, 2018 5:09:00 PM

The new European Medical Device Regulation (MDR)


The actual Medical Device Directive (MDD) 93/42/EEC [1]and the Active Implantable Medical Device Directive (AIMDD) 90/385/ECC [2]are the basic directives for all kinds of medical devices in Europe. These directives are mandatory for all member states and have to be put into national legislation by the national parliaments within a given time limit. It is not allowed to reduce or change the requirements of the directive but the parliaments can implement additional requirements like the German “Medizinprodukteberater” (consultant for medical devices) in §31 of the German medical device law. 


In contrast to the Medical Device Directive the Medical Device Regulation (MDR) [3]comes directly from the European Commission in Brussels without any approval by the national parliaments and has to be applied as European, supranational law within a given time limit. Additional national requirements resolved by the national parliaments are possible.

One of the reasons for the new MDR was the PIP-scandal: One manufacturer used the cheaper industrial silicon for breast implants instead of the ultra-pure medical silicon. Once this scandal had been made known publicly the Commission decided to tighten up the directive to prevent this kind of criminal process.

Read More

Topics: Clinical Trial Methods

Posted by Dr. Carsten Benesch on Aug 2, 2018 5:12:00 PM

Clamp studies with ultra-long-acting insulins – New challenges for an old procedure

The euglycemic clamp technique has been used as a standard method for assessing time action profiles of insulins for decades. In recent years, new challenges have emerged for investigators performing glucose clamp trials. These are driven by two opposing trends in the development of novel insulins: On the one hand, drug developers are formulating insulin products with a very rapid onset of action and a short duration of action – often referred to as “ultra-rapid insulins” [1,2]. On the other hand, novel basal insulins are being developed with an “ultra-long” duration of action with flatter activity profiles than previously available products [3,4,5].


Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes, Diabetes Technology

Posted by Oliver Klein on Jul 24, 2018 5:11:00 PM

"Profil World" - The clinical diabetes research newsletter - July 2018

Dear all,

Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.

Read More

Topics: About Profil

Posted by Dr. Lars Bochmann on Jul 18, 2018 5:21:00 PM

Diabetes: A paradigm case for rewarding innovation in value-based healthcare

Chronic diseases in Europe account for 86% of deaths and 77% of disease burden, that impact on functional status and create a tremendous challenge on national economies. Ageing is a main driver of incident chronic diseases, which again trigger physical and mental vulnerability and morbidity. 

Read More

Topics: Treating Diabetes

Posted by Dr. Lars Bochmann on Jul 11, 2018 5:12:00 PM

Gut Microbiota and Type 2 Diabetes

For many years, microbes, e.g. bacteria, fungi, viruses and other microorganisms, have solely been associated with diseases and unhygienic conditions. In response, mankind has spared little effort to eradicate these organisms, be it in everyday life through ubiquitously available disinfectants or in a medical setting, e.g. through antibiotics or antifungal medication. While there are places where a germ-free environment is vital, e.g. an operation room, one needs to differentiate between spaces in which microorganisms physiologically should not exist (e.g. in our bloodstream) or spaces in which they should flourish (e.g. the colon).

Bearing this in mind, in recent years, researchers have found that the microorganisms living on and in our body (i.e. any surface connected to the outside world, e.g. skin, nasal and oral cavities, our gastrointestinal tract et cetera), our microbiota, are, in fact, not harmful to us. On the contrary, they may contribute to our health and well-being and protect us against actual pathogens (by forming a so-called “colonization resistance" [1]). In addition, research has revealed the complexity and diversity of our gut microbiota which may be in part responsible for the development of certain diseases including obesity and type 2 diabetes [2].

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes, Diabetes Technology

Posted by Dr. Theresa Herbrand on Jul 4, 2018 5:16:00 PM

Subscribe to our monthly blog updates

Neuer Call-to-Action 

Subscribe to Email Updates

Our most popular Posts